CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will present at the Noble Financial Capital Markets’ 12th Annual Investor and Equity Conference on Wednesday, January 20, 2016 at 10:00 am Eastern Time.
